RAS blockers: Does sex matter?. Re: Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure - A population study: Marie Hudson et al. European Journal of Heart Failure 9 (2007) 602-609

European Journal of Heart Failure

Volumn 9, Issue 9, 2007, Pages 963-964

  Strauss, Martin H ^a   Hall, Alistair ^b  

^a NORTH YORK GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; VALSARTAN;

ACUTE HEART INFARCTION; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; FOLLOW UP; HOSPITALIZATION; HUMAN; LETTER; MEDICAL PRACTICE; META ANALYSIS; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; MALE; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS;

EID: 34548349213     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.06.010     Document Type: Letter

References (10)

1. Hudson M., Rahme E., Behlouli H., Sheppard R., and Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - a population study. Eur J Heart Fail 9 6-7 (June 2007) 602-609
2. Strauss M.H., and Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114 8 (August 22 2006) 838-854
3. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 9335 (September 7 2002) 752-760
4. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 20 (November 13 2003) 1893-1906
5. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41 9 (May 7 2003) 1529-1538
6. Tsuyuki R.T., and McDonald M.A. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 114 8 (August 22 2006) 855-860
7. Verdecchia P., Angeli F., Gattobigio R., and Reboldi G.P. Do angiotensin II receptor blockers increase the risk of myocardial infarction?. Eur Heart J 26 22 (November 2005) 2381-2386
8. Volpe M., Mancia G., and Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 23 12 (December 2005) 2113-2118
9. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens May 2007;25(5):951--8.
10. Verdecchia P., Reboldi G., Angeli F., et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46 2 (August 2005) 386-392